Today: 28 June 2026
Browse Category

Biotechnology 7 January 2026 - 12 January 2026

Twist Bioscience stock jumps on early revenue beat as TWST investors eye JPM talk and Feb. 2 results

Twist Bioscience stock jumps on early revenue beat as TWST investors eye JPM talk and Feb. 2 results

Twist Bioscience shares rose nearly 8% Monday after preliminary fiscal Q1 revenue reached about $103.7 million, beating company forecasts. DNA Synthesis and Protein Solutions sales climbed 27% to $51.1 million, while NGS Applications revenue hit $52.6 million. CEO Emily Leproust cited strong demand in both segments. Full audited results are due Feb. 2.
12 January 2026
··
Moderna stock slides as $1.9 billion sales view fails to calm investors (MRNA)

Moderna stock slides as $1.9 billion sales view fails to calm investors (MRNA)

Moderna shares fell 4% to $32.92 Monday after the company raised its 2025 revenue forecast to $1.9 billion and projected operating expenses of up to $5.2 billion. CFO Jamey Mock said U.S. retail vaccination rates dropped 26% in 2025. The company expects about $8.1 billion in year-end cash, including $600 million from a new loan. Investors remain cautious as pandemic demand fades and late-stage vaccine trial results approach.
12 January 2026
···
CG Oncology stock (CGON) jumps 29% on faster Phase 3 timeline — what to watch next week

CG Oncology stock (CGON) jumps 29% on faster Phase 3 timeline — what to watch next week

CG Oncology shares surged 29.3% to $54.20 after the company moved up its Phase 3 PIVOT-006 trial timeline, now expecting topline results in early 2026. Trading volume reached 7 million shares. Analysts raised price targets following the update and ahead of the JPMorgan Healthcare Conference. The trial enrolls over 360 bladder cancer patients and measures recurrence-free survival.
12 January 2026
··
CRISPR Therapeutics stock (CRSP) drops into JPM week — what to watch next

CRISPR Therapeutics stock (CRSP) drops into JPM week — what to watch next

CRISPR Therapeutics shares fell 4.5% to $53.84 Friday ahead of its Monday presentation at the J.P. Morgan Healthcare Conference. Investors are focused on updates for Casgevy’s commercial rollout, patient starts, and payer coverage. The therapy, approved for sickle cell disease, is co-developed with Vertex, which records product revenue. Traders await signals on 2026 projections and revenue ramp-up.
12 January 2026
··
Regencell Bioscience (RGC) stock swings 45% then closes up 10.6% — what to watch Monday

Regencell Bioscience (RGC) stock swings 45% then closes up 10.6% — what to watch Monday

Regencell Bioscience shares closed Friday up 10.6% at $45.79 after swinging between $35.13 and $50.92 on heavy volume. The company disclosed a DOJ subpoena and warned of possible legal penalties and funding risks in its Oct. 31 annual report. Its auditor expressed “substantial doubt” about Regencell’s ability to continue as a going concern. No new corporate updates have been posted since the annual filing.
11 January 2026
··
Wave Life Sciences stock drops 7% into JPM Healthcare Conference week — what to know next

Wave Life Sciences stock drops 7% into JPM Healthcare Conference week — what to know next

Wave Life Sciences shares fell 6.7% to $13.84 Friday, underperforming biotech peers ahead of the J.P. Morgan Healthcare Conference. Investors are watching for CEO Paul Bolno’s Tuesday update on WVE-007, its obesity drug, after December’s interim data showed a 9.4% visceral fat reduction. The company recently raised $350 million in a public offering.
11 January 2026
··
CG Oncology stock jumps 29% on faster Phase 3 PIVOT-006 data clock — what to watch next

CG Oncology stock jumps 29% on faster Phase 3 PIVOT-006 data clock — what to watch next

CG Oncology shares jumped nearly 29% Friday, closing at $54.20, after the company said topline Phase 3 trial data for its bladder cancer therapy will arrive in the first half of 2026, almost a year early. Morgan Stanley raised its price target to $93, citing the accelerated timeline. The PIVOT-006 trial enrolled over 360 patients at more than 90 sites.
11 January 2026
··
Lilly’s TuneLab AI drug platform lands in Schrödinger LiveDesign as biotech access broadens

Lilly’s TuneLab AI drug platform lands in Schrödinger LiveDesign as biotech access broadens

Schrödinger will integrate Eli Lilly’s AI drug discovery platform, TuneLab, into its LiveDesign software, giving biotech teams direct access to Lilly’s predictive models. Revvity and Benchling also announced deals to offer TuneLab through their platforms. Lilly and Revvity will jointly fund access for select users, using federated learning to protect data. BigHat Biosciences will collaborate with Lilly to improve antibody developability models.
10 January 2026
····
CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics shares fell 4.3% to $54.00 after a filing showed CFO Raju Prasad exercised and sold 29,700 shares under a preset trading plan. The move comes ahead of the company’s Jan. 12 slot at the J.P. Morgan Healthcare Conference and an expected mid-February earnings report. Gene-editing peers also traded lower. CASGEVY revenue and rollout remain key investor focus.
9 January 2026
·······
CG Oncology stock jumps 25% after pulling Phase 3 PIVOT-006 bladder cancer data into 1H 2026

CG Oncology stock jumps 25% after pulling Phase 3 PIVOT-006 bladder cancer data into 1H 2026

CG Oncology shares surged 25.1% to $52.45 after the company advanced the expected release of late-stage bladder cancer trial results to the first half of 2026. The PIVOT-006 Phase 3 trial enrolled over 360 patients and compares cretostimogene grenadenorepvec to surveillance after tumor removal. Trading volume topped 4.1 million shares by midday. Morgan Stanley raised its price target on the stock to $89.
9 January 2026
···
Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

Merck shares rose 1.5% to $110.20 after Wolfe Research upgraded the stock and set a $135 price target. Merck completed its $221.50-per-share tender offer for Cidara and flagged a $9 billion R&D charge for 2026. Investors watched fallout from a U.S. shift to a single-dose HPV vaccine recommendation ahead of Merck’s Feb. 3 results.
8 January 2026
····
Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update

Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update

Immuneering shares surged 24% to $8.33 premarket after reporting 64% overall 12-month survival in a 34-patient Phase 2a pancreatic cancer trial. The company compared this to a 35% benchmark from standard chemotherapy. Median progression-free survival reached 8.5 months. Immuneering plans a larger data update and to start a Phase 3 trial in mid-2026.
8 January 2026
···
Amgen stock jumps on UBS buy call as Dark Blue deal sharpens focus on pipeline

Amgen stock jumps on UBS buy call as Dark Blue deal sharpens focus on pipeline

Amgen shares rose 3.5% to $341.64 after UBS initiated coverage with a buy rating and a $380 target. The move follows FDA approval of Amneal’s biosimilar rivals to Amgen’s Prolia and Xgeva, which generated $5.3 billion in U.S. sales last year. Amgen also announced an $840 million deal to acquire Dark Blue Therapeutics, adding an early-stage leukemia drug. CEO Robert Bradway will present at the J.P. Morgan Healthcare Conference on Jan. 12.
8 January 2026
···
1 … 5 6 7 8 9 … 19

Stock Market Today

  • M&G Emerges as a Leading FTSE 100 Dividend Stock: Five Key Reasons
    June 28, 2026, 5:41 AM EDT. M&G (LSE:MNG) has become one of the FTSE 100's top dividend stocks since its 2019 spin-off from Prudential, with annual dividend increases reflecting resilience and robust cash flows. Its dividend yield has averaged 6.3%, significantly outpacing the FTSE 100 average of 3-4%. The company's strong Solvency II capital ratio and a conservative cash-flow-to-payout ratio of 63% support a progressive and sustainable dividend policy. Despite competitive pressures from peers like Aviva and Legal & General, M&G's solid execution and brand strength underpin confidence in ongoing dividend growth. Investors are advised to consider these factors carefully before buying shares.

Latest articles

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 28.06.2026

28 June 2026
LIVEMarkets rolling coverageStarted: June 28, 2026, 4:00 AM EDTUpdated: June 28, 2026, 5:49 AM EDT M&G Emerges as a Leading FTSE 100 Dividend Stock: Five Key Reasons June 28, 2026, 5:41 AM EDT. M&G (LSE:MNG) has become one of the FTSE 100’s top dividend stocks since its 2019 spin-off from Prudential, with annual dividend increases reflecting resilience and robust cash flows. Its dividend yield has averaged 6.3%, significantly outpacing the FTSE 100 average of 3-4%. The company’s strong Solvency II capital ratio and a conservative cash-flow-to-payout ratio of 63% support a progressive and sustainable dividend policy. Despite competitive pressures from
Go toTop